AstraZeneca
NEWS
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
The importance of artificial intelligence and machine learning is ever-increasing in the world of drug development and AstraZeneca is bolstering its participation in the tech revolution by striking a deal with New York-based Schrodinger to use that company’s advanced computing platform to help accelerate drug discovery efforts.
AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
Breztri Aerosphere is a triple combination drug of budesonide, glycopyrronium and formoterol fumarate.
AstraZeneca said the FDA awarded the designation to Farxiga to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
The Phase III NEPTUNE trial assessed the combination treatment as a first-line treatment in an “all-comers population,” with the primary analysis population being patients with a high tumor mutational burden.
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
JOBS
IN THE PRESS